Previous Close | 40.34 |
Open | 41.16 |
Bid | 41.50 x 1800 |
Ask | 41.63 x 900 |
Day's Range | 40.57 - 43.06 |
52 Week Range | 34.88 - 277.80 |
Volume | |
Avg. Volume | 7,493,135 |
Market Cap | 3.244B |
Beta (5Y Monthly) | 1.51 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -17.51 |
Earnings Date | Nov 02, 2022 - Nov 07, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 124.60 |
Subscribe to Yahoo Finance Plus to view Fair Value for NVAX
Commission-free trading platform Robinhood Markets grew in prominence helping newer investors participate in what remains one of the best ways to accumulate wealth over time. One example is Ocugen (NASDAQ: OCGN). Can Ocugen succeed in the COVID-19 vaccine market?
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that partner, SK bioscience, has received a Post Approval Change Application approval from the Korean Ministry of Food and Drug Safety (KMFDS) for Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-
A hugely disappointing quarter and new bear takes on the company by analysts made for a very bad set of trading days.